查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014470

藥物發現技術市場：2026年至2032年全球市場預測（按藥物類型、檢測方法、技術平台、應用和最終用戶分類）

Drug Discovery Technologies Market by Drug Type, Assay Techniques, Technology Platforms, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，藥物發現技術市場價值將達到 701.9 億美元，到 2026 年將成長至 775.9 億美元，到 2032 年將達到 1,458 億美元，複合年成長率為 11.00%。

主要市場統計數據
基準年 2025 701.9億美元
預計年份：2026年 775.9億美元
預測年份 2032 1458億美元
複合年成長率 (%) 11.00%

全面概述了重塑學術界、生物技術和製藥研究環境中藥物發現過程的技術的演變及其戰略意義。

藥物研發領域目前正經歷快速的技術成熟，這正在改變各機構識別標靶、檢驗作用機制以及推進候選化合物研發的方式。運算能力、偵測設計和跨學科整合的進步，使得研究團隊能夠縮短研發週期、降低早期失敗率，並獲得更可靠的臨床前證據。因此，學術界、生技公司和製藥業的相關人員正在重新思考資源分配、夥伴關係模式和基礎設施投資，以確保能夠充分利用這些技術所帶來的生產力提升。

計算建模、檢測創新和轉化基因組學的進步的融合，從根本上改變了目標選擇、檢驗和合作模式。

藥物發現領域發生了多項變革性變化，這些變化如今正在匯聚，並重新調整整個研究生態系統的優先事項。首先，計算建模和基於結構的藥物設計的普及重新分配了專業知識，使小規模的團隊能夠利用In Silico先導化合物最佳化和預測藥理學來攻克複雜的靶點。同時，高通量篩檢平台和基於奈米技術的檢測方法的廣泛應用，大大增加了可用於檢驗早期先導化合物的實驗組合數量，從而產生了更為豐富的資料集，而這些資料集需要強大的資訊學流程來處理。

到 2025 年，美國關稅政策的變化對營運的影響，以及貿易措施如何重塑藥物研發領域的供應鏈韌性和籌資策略。

到2025年，美國不斷變化的關稅政策的累積影響正對全球藥物研發供應鏈和設備籌資策略產生重大的營運挑戰。影響試劑、實驗室耗材和某些設備類別的關稅和貿易措施正在增加跨境採購的間接成本，迫使採購團隊實現供應商多元化並重新評估庫存策略。實際上，生產和採購高度集中的企業正面臨更長的前置作業時間週期和更高的接收成本，這促使它們轉向近岸外包和本地採購，以滿足關鍵投入品的需求。

針對特定細分市場的策略性洞察揭示了藥物類型、檢測技術、技術平台、應用領域和最終用戶目標的差異如何影響藥物發現過程。

基於細分的洞察揭示了藥物發現各子領域在研發路徑和技術應用方面存在顯著差異。從藥物類型來看，生物製藥傾向於優先採用能夠捕捉複雜蛋白質相互作用和細胞環境的檢測方法，而小分子藥物則仍然偏好高通量生化和結合檢測，以儘早發現先導化合物。這種差異影響著上游工程投資，生物製藥計畫傾向於將更多資源投入到能夠評估功能結果的細胞檢測和報告系統，而小分子藥物計畫則優先考慮基於結構的藥物設計和快速高通量篩選。

美洲、歐洲、中東和非洲以及亞太地區的區域優勢和政策環境如何定義基於互補能力和協作的價值鏈？

區域趨勢是藥物研發投資和能力集中方向的重要促進因素。在美洲，成熟的創投生態系統和完善的生物製造工業基礎設施為快速商業化提供了支持，研發中心通常將計算科學和高通量平台與臨床開發專業知識相結合。該地區的法規結構和醫保環境也影響轉化研究的重點，從而促進了在研發早期階段就產生臨床可用生物標記證據的計畫。

透過平台專業化、策略聯盟和可擴展的服務交付，確定藥物發現領域競爭地位的企業策略和夥伴關係模式。

企業級藥物研發技術的發展趨勢反映了專業化、策略聯盟和垂直整合的整合。主要企業正日益透過結合電腦設計、客製化檢測平台和檢驗的生物模型的專有平台來建立競爭優勢。許多企業正尋求夥伴關係主導型模式，透過與專業供應商、受託研究機構(CRO) 和學術機構合作，加速能力獲取，擴展處理能力和專業知識，而無需承擔全部內部研發成本。

切實可行的策略措施，使高階主管能夠透過有針對性的投資，建立強大的韌性能力，降低專案風險，並加速轉換成果。

希望維持產業領先地位的領導企業應採取一系列切實可行的措施，使能力建設投資與組織的風險接受度和轉化研究重點保持一致。首先，應制定模組化的技術藍圖，依序投資於計算建模、高通量篩檢和生理相關檢測。這將確保每個新增要素都能大幅降低關鍵研發決策的風險。同時，應優先考慮供應鏈多元化和合約柔軟性，以減少貿易政策和對單一供應商依賴所帶來的干擾。

結合一手訪談、諮商領域專家和全面文獻整合的多方法研究框架，支持穩健的策略分析。

本研究採用多種方法，結合一手訪談、專家諮詢以及對同行評審文獻和監管指南的系統性回顧，以確保分析的平衡性和實證性。一手研究包括與研發部門高階領導、採購經理和技術供應商進行結構化討論，以了解實際營運和策略重點。專家諮詢則透過提供關於檢測驗證、藥物基因體學學整合和平台互通性領域的專業觀點，對這些訪談進行了補充。

整合領導者必須採取的策略挑戰和營運重點，以將技術進步轉化為可複製的轉化成果。

總之，藥物研發發生態系統正朝著整合計算科學、檢測和轉化研究能力的一體化模式轉變，以提高早期研發的準確性和效率。這些變化正在重塑組織的優先事項，從檢測方法的選擇到供應鏈的構建，都需如此，並要求領導者採取模組化的投資策略，加強跨學科團隊建設，並建立正式的夥伴關係以充分利用專業能力。貿易政策趨勢和區域優勢進一步增加了決策的複雜性，同時也為跨區域策略合作創造了機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 藥物發現技術市場（依藥物類型分類）

  • 生物製藥
  • 小分子藥物

第9章 依檢測方法分類的藥物發現技術市場

  • 結合試驗
  • 生化分析
  • 基於細胞的檢測
  • 報導基因分析

第10章 依技術平台分類的藥物發現技術市場

  • 計算建模
  • 高通量篩檢
  • 奈米科技
  • 藥物基因體學
  • 結構設計

第11章 藥物發現技術市場：依應用領域分類

  • 生物標記生成
  • 先導化合物搜尋
  • 臨床前和臨床開發
  • 目標識別與檢驗
  • 毒性測試

第12章 藥物發現技術市場：依最終用戶分類

  • 學術機構
  • 生技公司
  • 製藥公司

第13章 藥物發現技術市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 藥物發現技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 藥物發現技術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國藥物發現技術市場

第17章：中國藥物研發技術市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer Healthcare AG
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Covaris, LLC
  • Curia Global, Inc.
  • Elucidata Corporation
  • Eurofins Advinus Private Limited
  • Evotec SE
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare Ltd.
  • Gilead Sciences, Inc.
  • Horiba, Ltd.
  • Illumina, Inc.
  • IQVIA Inc.
  • Luminex Corporation by DiaSorin Group
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • PIRAMAL PHARMA LIMITED
  • Randox Laboratories Ltd.
  • Revolution Medicines, Inc.
  • Sanofi SA
  • Sygnature Discovery Limited
  • Syngene International Limited
  • Thermo FIsher Scientific Inc.
  • VWR International LLC
  • WuXi AppTec Co., Ltd.
Product Code: MRR-4348D129FA8B

The Drug Discovery Technologies Market was valued at USD 70.19 billion in 2025 and is projected to grow to USD 77.59 billion in 2026, with a CAGR of 11.00%, reaching USD 145.80 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 70.19 billion
Estimated Year [2026] USD 77.59 billion
Forecast Year [2032] USD 145.80 billion
CAGR (%) 11.00%

An integrative overview of technological evolution and strategic implications reshaping drug discovery processes across academic, biotech, and pharmaceutical research environments

The drug discovery landscape is undergoing a period of rapid technical maturation that is reshaping how organizations identify targets, validate mechanisms, and progress candidates toward development. Advances in computational capabilities, assay design, and cross-disciplinary integration are enabling research teams to compress cycles, reduce attrition in early stages, and generate higher-fidelity preclinical evidence. Consequently, stakeholders across academic, biotech, and pharmaceutical settings are re-evaluating resource allocation, partnership models, and infrastructure investments to capture the productivity gains these technologies promise.

This introduction frames the core themes addressed in the report: the convergence of wet-lab and in-silico techniques, the prioritization of translational biomarkers, and the operational implications of distributed research networks. By situating these developments within the broader R&D continuum, readers can appreciate how incremental improvements in hit identification or assay sensitivity cascade into significant changes in downstream decision gates. The ensuing sections synthesize technological trajectories, regulatory touchpoints, and commercial strategies so that leaders can make informed choices grounded in contemporary evidence rather than legacy assumptions.

How converging advances in computational modeling, assay innovation, and translational genomics are fundamentally altering target selection, validation, and collaboration models

The landscape of drug discovery has experienced several transformative shifts that are now converging to alter priorities across the research ecosystem. First, the democratization of computational modeling and structure-based design has redistributed expertise, enabling smaller teams to pursue complex targets with in-silico lead optimization and predictive pharmacology. At the same time, the proliferation of high-throughput screening platforms and nanotechnology-enhanced assay formats has multiplied the experimental permutations available for early hit validation, producing richer datasets that demand robust informatics pipelines.

Additionally, pharmacogenomics is moving from a niche precision-medicine enabler to an integral consideration in preclinical design, influencing target selection and biomarker strategies. These shifts are reinforced by an increasing emphasis on reproducibility and translational relevance, which has prompted investment in more physiologically relevant cell-based assays and reporter gene constructs that better model human biology. As a result, collaborative consortia and cross-sector partnerships are becoming the dominant operational model, combining specialized capabilities and distributing risk. Therefore, strategic planning must accommodate faster iteration cycles, multidisciplinary skill sets, and scalable data architectures to capture the full value of these transformative changes.

The operational consequences of evolving US tariff policies through 2025 and how trade measures are reshaping supply chain resilience and procurement strategies in drug discovery

The cumulative influence of US tariff policy as it has evolved into 2025 has imposed substantive operational considerations for global drug discovery supply chains and equipment procurement strategies. Tariffs and trade measures affecting reagents, laboratory consumables, and certain instrumentation categories have increased the indirect cost of cross-border sourcing, prompting procurement teams to reassess supplier diversification and inventory strategies. In practical terms, organizations with centralized manufacturing and procurement footprints have faced longer lead times and higher landed costs, incentivizing nearshoring or regional sourcing arrangements for mission-critical inputs.

Moreover, tariff-driven shifts have accentuated the strategic value of domestic manufacturing partnerships and modular procurement frameworks that can adapt to episodic trade restrictions. For research programs that rely on specialized reagents or bespoke assay kits, the ripple effects have included renegotiated supplier terms, an emphasis on validated equivalence of alternative reagents, and expanded use of contract development and manufacturing organizations with regional capabilities. Simultaneously, regulatory-compliant documentation for origin and supply chain traceability has grown in importance to avoid customs-related delays. Taken together, these dynamics have not only increased operational complexity but have also accelerated the trend toward resilient, region-aware supply chain architectures within drug discovery organizations.

Segment-driven strategic insights revealing how variations in drug type, assay techniques, technology platforms, application areas, and end-user objectives shape discovery pathways

Segmentation-driven insights reveal meaningful heterogeneity in development pathways and technology adoption across drug discovery subdomains. When viewed through the lens of drug type, Biologic Drugs tend to prioritize assays that capture complex protein interactions and cellular context, while Small-Molecule Drugs continue to favor high-throughput biochemical and binding assays for initial hit identification. This dichotomy influences upstream investments, with biologics programs often allocating greater resources to cell-based assays and reporter systems that can assess functional outcomes, whereas small-molecule efforts emphasize structure-based design and rapid screening throughput.

Assay technique segmentation underscores the interplay between binding assays, biochemical assays, cell based assays, and reporter gene assays in constructing a tiered validation strategy. Each technique serves distinct decision points: binding and biochemical assays rapidly characterize interaction and enzymatic modulation; cell based and reporter gene assays provide phenotypic relevance and pathway-level confirmation. Technology platform segmentation further clarifies capability differentials, as computational modeling and structure-based design accelerate in-silico triage, high throughput screening scales empirical testing, nanotechnology introduces novel delivery and surface-interaction modalities, and pharmacogenomics informs target prioritization through human genetic context.

Application-based segmentation-spanning biomarker discovery, lead discovery, preclinical and clinical development, target identification and validation, and toxicology testing-illustrates how different stages demand unique combinations of assays and platforms. Biomarker discovery and target validation lean on genomics-integrated approaches and physiologically relevant assays, whereas preclinical development and toxicology testing require stringent reproducibility, cross-platform concordance, and regulatory-grade documentation. Finally, end-user segmentation highlights that academic institutions, biotechnology firms, and pharmaceutical companies apply these tools for divergent objectives: academia frequently focuses on exploratory validation and novel biology, biotechnology firms prioritize translational proof-of-concept and platform differentiation, and pharmaceutical companies concentrate on risk-managed development pipelines and scalable manufacturing readiness. These segmentation insights collectively inform investment prioritization, partnership selection, and the operational sequencing of discovery activities.

How regional strengths and policy environments across the Americas, Europe Middle East & Africa, and Asia-Pacific define complementary capabilities and collaborative value chains

Regional dynamics are a powerful determinant of where and how drug discovery investments and capabilities are concentrated. In the Americas, a mature venture ecosystem and established industrial biomanufacturing base support rapid commercialization pathways, with R&D centers frequently integrating computational and high-throughput platforms alongside clinical development expertise. Regulatory frameworks and reimbursement environments in this region also influence the translational emphasis, encouraging programs that generate clinically actionable biomarker evidence early in the development cycle.

Europe, Middle East & Africa exhibits a mosaic of strengths including advanced academic research hubs, collaborative public-private consortia, and pockets of specialized biotech clusters. Cross-border collaboration and harmonized regulatory initiatives within parts of this region facilitate multicenter validation studies and comparative effectiveness research, even as geopolitical and funding variability introduce complexity for long-term program planning. Infrastructure investments and policy incentives in certain markets have catalyzed translational networks that connect discovery science with patient-centric clinical research.

Asia-Pacific demonstrates accelerating capacity across both research-intensive nations and emerging biotech markets, with significant public and private investment in high-throughput platforms, computational resources, and manufacturing scale-up. The region's emphasis on rapid iteration, cost-effective operational models, and localized supply chain development has made it a central node for both early-stage discovery activities and downstream production readiness. Consequently, cross-regional collaboration strategies often pair Americas-based clinical expertise with Asia-Pacific manufacturing agility and Europe's translational science strengths to create complementary value chains.

Corporate strategies and partnership models that determine competitive positioning through platform specialization, strategic alliances, and scalable service delivery in discovery

Company-level dynamics in drug discovery technology reflect a blend of specialization, strategic alliances, and vertical integration. Leading organizations are increasingly defining competitive advantage through proprietary platforms that combine computational design, bespoke assay panels, and validated biological models. Many firms pursue partnership-led models to accelerate capability acquisition, entering into collaborations with specialized vendors, contract research organizations, and academic centers to expand throughput and domain expertise without bearing the full cost of in-house development.

Mergers, licensing agreements, and targeted acquisitions have been used selectively to internalize high-value technologies or to secure access to unique reagent portfolios and clinical biomarker datasets. At the same time, companies are experimenting with alternative commercialization strategies, including platform-as-a-service offerings and data-access subscriptions, which realign revenue models around recurring service relationships rather than one-time sales. Intellectual property management, data governance, and regulatory positioning remain core differentiators as firms scale from exploratory programs to late-stage development. Consequently, corporate strategies increasingly emphasize interoperable technology stacks, robust validation frameworks, and commercial models that balance upfront investment with scalable service delivery.

Practical, high-impact strategic measures for executives to build resilient capabilities, de-risk pipelines, and accelerate translational outcomes through targeted investments

Industry leaders that intend to stay at the forefront should adopt a set of actionable measures that align capability investment with organizational risk appetite and translational priorities. Begin by establishing modular technology roadmaps that sequence investments in computational modeling, high-throughput screening, and physiologically relevant assays so that each addition demonstrably lowers decision risk at key development gates. Simultaneously, prioritize supply chain diversification and contractual flexibility to mitigate disruptions related to trade policy or single-source dependencies.

Invest in data infrastructure and governance frameworks that enable cross-platform integration and reproducibility, ensuring that computational outputs and experimental results can be validated and audited for regulatory submission. Pursue collaborative partnerships with academic labs and specialized vendors to access niche expertise while retaining core competencies internally. Finally, align talent strategies with these technological priorities by recruiting multidisciplinary teams that combine wet-lab experience, data science proficiency, and regulatory know-how, and provide continuous learning pathways to adapt to emergent methodologies. These actions will create a resilient operational foundation and accelerate the translation of discovery-stage insights into clinically meaningful outcomes.

A multi-method research framework blending primary interviews, domain expert consultations, and comprehensive literature synthesis to underpin robust strategic analysis

This research synthesizes a multi-method approach combining primary interviews, expert consultations, and systematic review of peer-reviewed literature and regulatory guidance to ensure a balanced and empirically grounded analysis. Primary research involved structured discussions with senior R&D leaders, procurement managers, and technology vendors to capture operational realities and strategic priorities. Expert consultations supplemented these interviews with domain-specific perspectives on assay validation, pharmacogenomic integration, and platform interoperability.

Secondary research incorporated recent literature in computational chemistry, assay development, and translational biomarker science, along with policy documents that clarify regulatory expectations for preclinical validation and supply chain traceability. Analytical methods included cross-sectional comparisons across segmentation and regional dimensions, qualitative coding of expert inputs to identify recurring themes, and scenario-based assessments to explore operational implications of trade and regulatory shifts. Throughout, methodological rigor was maintained through triangulation of sources and transparent documentation of data provenance to support confidence in the conclusions and recommendations.

Synthesis of strategic imperatives and operational priorities that leaders must adopt to translate technological advances into reproducible translational outcomes

In conclusion, the drug discovery ecosystem is transitioning toward an integrated model where computational, assay, and translational capabilities converge to increase the fidelity and efficiency of early-stage development. These changes are reshaping organizational priorities, from how assays are selected to how supply chains are structured, and they demand that leaders adopt modular investment strategies, strengthen cross-disciplinary teams, and formalize partnerships to access specialized capabilities. Trade policy dynamics and regional strengths further complicate decision-making but also present opportunities for strategic alignment across geographies.

Moving forward, success will favor organizations that combine rigorous data practices, flexible procurement strategies, and a clear linkage between technical investments and downstream clinical objectives. By adopting the actionable recommendations detailed in this report and maintaining adaptive governance practices, stakeholders can translate technological potential into reproducible, clinically relevant outcomes that withstand operational and policy headwinds.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Technologies Market, by Drug Type

  • 8.1. Biologic Drugs
  • 8.2. Small-Molecule Drugs

9. Drug Discovery Technologies Market, by Assay Techniques

  • 9.1. Binding Assays
  • 9.2. Biochemical Assays
  • 9.3. Cell Based Assays
  • 9.4. Reporter Gene Assays

10. Drug Discovery Technologies Market, by Technology Platforms

  • 10.1. Computational Modeling
  • 10.2. High Throughput Screening
  • 10.3. Nanotechnology
  • 10.4. Pharmacogenomics
  • 10.5. Structure Based Design

11. Drug Discovery Technologies Market, by Application

  • 11.1. Biomarker Discovery
  • 11.2. Lead Discovery
  • 11.3. Preclinical & Clinical Development
  • 11.4. Target Identification & Validation
  • 11.5. Toxicology Testing

12. Drug Discovery Technologies Market, by End User

  • 12.1. Academic Institutions
  • 12.2. Biotechnology Firms
  • 12.3. Pharmaceutical Companies

13. Drug Discovery Technologies Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug Discovery Technologies Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Discovery Technologies Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Drug Discovery Technologies Market

17. China Drug Discovery Technologies Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories, Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer Healthcare AG
  • 18.9. Bio-Rad Laboratories, Inc.
  • 18.10. bioMerieux SA
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Covaris, LLC
  • 18.13. Curia Global, Inc.
  • 18.14. Elucidata Corporation
  • 18.15. Eurofins Advinus Private Limited
  • 18.16. Evotec SE
  • 18.17. F. Hoffmann-La Roche Ltd.
  • 18.18. GE Healthcare Ltd.
  • 18.19. Gilead Sciences, Inc.
  • 18.20. Horiba, Ltd.
  • 18.21. Illumina, Inc.
  • 18.22. IQVIA Inc.
  • 18.23. Luminex Corporation by DiaSorin Group
  • 18.24. Merck & Co., Inc.
  • 18.25. Novartis AG
  • 18.26. Pfizer Inc.
  • 18.27. PIRAMAL PHARMA LIMITED
  • 18.28. Randox Laboratories Ltd.
  • 18.29. Revolution Medicines, Inc.
  • 18.30. Sanofi S.A.
  • 18.31. Sygnature Discovery Limited
  • 18.32. Syngene International Limited
  • 18.33. Thermo FIsher Scientific Inc.
  • 18.34. VWR International LLC
  • 18.35. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOLOGIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOLOGIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BINDING ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BINDING ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BINDING ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY CELL BASED ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY CELL BASED ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY CELL BASED ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REPORTER GENE ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REPORTER GENE ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REPORTER GENE ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COMPUTATIONAL MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COMPUTATIONAL MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COMPUTATIONAL MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STRUCTURE BASED DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STRUCTURE BASED DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PRECLINICAL & CLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PRECLINICAL & CLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PRECLINICAL & CLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TOXICOLOGY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TOXICOLOGY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 123. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 124. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 141. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 142. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 147. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 148. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)